STAT+: Ted Love, BIO’s first Black board chair, aims to rehab biotech’s image in Washington
“It's not just about profits. It certainly is not about us as individuals. It's about something much bigger. It’s really about the patient,” BIO’s new board chair told STAT.
WASHINGTON — Ted Love has pretty much done everything there is to do in biotech.
He’s worked for tiny startups and mega corporations. He sold his latest company to Pfizer for $5 billion amid an industry downturn. And now, he’s taking on a new challenge by becoming the chair of the board of the largest biotechnology lobby, BIO.
He hopes to use his experience across the drug development process to improve the biotech industry’s reputation in Washington, following a bruising lobbying fight the industry lost when Democrats gave Medicare the power to negotiate drug prices, and the organization’s messy separation from its former CEO last year.
What's Your Reaction?
